Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

Phase 1

Terminated

Conditions: Skin Cancer
Metastatic Melanoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: IL-12 transduced TIL

First Posted Date: 2010-11-07

Last Posted Date: 2015-11-26

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 34

Registration Number: NCT01236573

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

Phase 3

Completed

Conditions: Hematopoietic and Lymphoid Cell Neoplasm
Myelodysplastic Syndrome
Recurrent Plasma Cell Myeloma
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
Refractory Chronic Lymphocytic Leukemia
Waldenstrom Macroglobulinemia
Aggressive Non-Hodgkin Lymphoma
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Small Lymphocytic Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
Drug: Sirolimus

First Posted Date: 2010-11-01

Last Posted Date: 2019-10-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 174

Registration Number: NCT01231412

Locations: 🇺🇸
University of Colorado, Denver, Colorado, United States
🇺🇸
Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

and more 8 locations

CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer

Phase 1

Terminated

Conditions: Metastatic Cancer
Metastatic Melanoma
Renal Cancer

Interventions: Biological: Anti-VEGFR2 CAR CD8 plus PBL
Drug: Cyclophosphamide
Biological: Aldesleukin
Drug: Fludarabine

First Posted Date: 2010-10-11

Last Posted Date: 2019-12-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT01218867

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer

Phase 1

Terminated

Conditions: Breast Cancer
Colorectal Cancer
Gastric Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2010-10-01

Last Posted Date: 2012-02-28

Lead Sponsor: Cancer Research UK

Target Recruit Count: 14

Registration Number: NCT01212887

Locations: 🇬🇧
Christie Hospital, Manchester, England, United Kingdom

Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

Phase 1

Recruiting

Conditions: Hematologic Malignancies

Interventions: Drug: Fludarabine
Drug: Cytoxan
Radiation: Total Body Irradiation
Procedure: Allogeneic Blood or Marrow Transplant
Procedure: Peripheral Blood Stem Cell Transplant
Drug: Mycophenolate Mofetil
Drug: Sirolimus
Drug: Tacrolimus

First Posted Date: 2010-09-16

Last Posted Date: 2024-03-13

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 100

Registration Number: NCT01203722

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

Phase 2

Completed

Conditions: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Interventions: Drug: Busulfan
Drug: Fludarabine

First Posted Date: 2010-09-16

Last Posted Date: 2023-07-13

Lead Sponsor: West Virginia University

Target Recruit Count: 22

Registration Number: NCT01203020

Locations: 🇺🇸
West Virginia University Hospitals Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States

A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia

Phase 1

Completed

Conditions: Neutropenia
Aplastic Anemia
Pancytopenia
Severe Aplastic Anemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2010-08-23

Last Posted Date: 2021-07-02

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 1

Registration Number: NCT01187017

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Fludarabine
Drug: Velcade
Drug: Rituximab

First Posted Date: 2010-08-23

Last Posted Date: 2016-10-24

Lead Sponsor: Hoosier Cancer Research Network

Target Recruit Count: 4

Registration Number: NCT01186458

Locations: 🇺🇸
Virtua Health Cancer Program, Mount Holly, New Jersey, United States
🇺🇸
South Jersey Health Care, Vineland, New Jersey, United States
🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 8 locations

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia

Interventions: Drug: Rituximab
Biological: Interleukin-2
Biological: Natural killer cells
Drug: Cyclophosphamide
Drug: Methylprednisolone
Drug: Fludarabine

First Posted Date: 2010-08-13

Last Posted Date: 2018-02-06

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 16

Registration Number: NCT01181258

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Childhood Acute Lymphoblastic Leukemia in Remission
Childhood Acute Myeloid Leukemia in Remission

Interventions: Procedure: umbilical cord blood transplantation
Drug: fludarabine phosphate
Drug: cyclophosphamide
Biological: ex vivo-expanded cord blood progenitor cell infusion
Radiation: total-body irradiation
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: laboratory biomarker analysis

First Posted Date: 2010-08-05

Last Posted Date: 2019-03-05

Lead Sponsor: Nohla Therapeutics, Inc.

Target Recruit Count: 15

Registration Number: NCT01175785

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy